In this study, promoter capture Hi-C, ChIP-Seq, STARR-Seq and CRISPR technologies were used to study the action of coronary artery disease risk variants in hepatocyte cells of the liver.
Photographer: UEF/ Raija Törrönen
In this study, promoter capture Hi-C, ChIP-Seq, STARR-Seq and CRISPR technologies were used to study the action of coronary artery disease risk variants in hepatocyte cells of the liver.